CLOTILDIA - CLOpidogrel versus TIcagreLor for antiplatelet maintenance in DIAbetic patients
Project Objectives
The aim of the CLOTILDIA study is to compare the efficacy of high doses clopidogrel treatment (150 mg/day) versus ticagrelor (90 mg/twice daily) on the inhibition level of platelet reactivity and prevention of medium term ischemic events in patients affected by diabetes mellitus and undergoing coronary angioplasty.
Start/End Dates
April 2012 - January 2015; data analysis ongoing
Principal Investigator
- Dr. Fabio Mangiacapra - Principal Investigator
- Prof. Germano Di Sciascio
Host Institution
Campus Bio-Medico University of Rome
Other Institutions involved
Cardiovascular Center, OLV Hospital - Aalst, Belgium